Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
linagliptin
placebo
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion criteria:
- Type 2 diabetes mellitus
- HbA1c >= 7.0%
- Age >= 70 years
- Signed and dated written informed consent
Exclusion criteria:
- Myocardial infarction, stroke or TIA within 3 months prior to informed consent
- Impaired hepatic function
- Treatment with glitazones, GLP-1 analogues, DPP-4 inhibitors or rapid acting or pre-mixed insulins
- Treatment with anti-obesity drugs
Sites / Locations
- 1218.63.61005 Boehringer Ingelheim Investigational Site
- 1218.63.61006 Boehringer Ingelheim Investigational Site
- 1218.63.61003 Boehringer Ingelheim Investigational Site
- 1218.63.61002 Boehringer Ingelheim Investigational Site
- 1218.63.61007 Boehringer Ingelheim Investigational Site
- 1218.63.61001 Boehringer Ingelheim Investigational Site
- 1218.63.61004 Boehringer Ingelheim Investigational Site
- 1218.63.10008 Boehringer Ingelheim Investigational Site
- 1218.63.10003 Boehringer Ingelheim Investigational Site
- 1218.63.10005 Boehringer Ingelheim Investigational Site
- 1218.63.10007 Boehringer Ingelheim Investigational Site
- 1218.63.10006 Boehringer Ingelheim Investigational Site
- 1218.63.10001 Boehringer Ingelheim Investigational Site
- 1218.63.10002 Boehringer Ingelheim Investigational Site
- 1218.63.10004 Boehringer Ingelheim Investigational Site
- 1218.63.45007 Boehringer Ingelheim Investigational Site
- 1218.63.45002 Boehringer Ingelheim Investigational Site
- 1218.63.45003 Boehringer Ingelheim Investigational Site
- 1218.63.45001 Boehringer Ingelheim Investigational Site
- 1218.63.45008 Boehringer Ingelheim Investigational Site
- 1218.63.45006 Boehringer Ingelheim Investigational Site
- 1218.63.45004 Boehringer Ingelheim Investigational Site
- 1218.63.45005 Bispebjerg Hospital
- 1218.63.31008 Boehringer Ingelheim Investigational Site
- 1218.63.31007 Boehringer Ingelheim Investigational Site
- 1218.63.31012 Boehringer Ingelheim Investigational Site
- 1218.63.31014 Boehringer Ingelheim Investigational Site
- 1218.63.31009 Boehringer Ingelheim Investigational Site
- 1218.63.31001 Boehringer Ingelheim Investigational Site
- 1218.63.46004 Boehringer Ingelheim Investigational Site
- 1218.63.46003 Boehringer Ingelheim Investigational Site
- 1218.63.46001 Boehringer Ingelheim Investigational Site
- 1218.63.46002 Boehringer Ingelheim Investigational Site
- 1218.63.46005 Boehringer Ingelheim Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
linagliptin
placebo
Arm Description
patients receive linagliptin 5 mg tablets once daily
patients receive placebo tablets matching linagliptin 5 mg once daily
Outcomes
Primary Outcome Measures
HbA1c Change From Baseline to Week 24
HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and prior use of insulin.
Secondary Outcome Measures
HbA1c Change From Baseline to Week 6
HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 6 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and prior use of insulin.
HbA1c Change From Baseline to Week 12
HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and prior use of insulin.
HbA1c Change From Baseline to Week 18
HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and prior use of insulin.
FPG Change From Baseline to Week 24
This change from baseline reflects the Week 24 FPG minus the baseline FPG. Means are treatment-adjusted for baseline HbA1c, baseline FPG and prior use of insulin.
FPG Change From Baseline to Week 6
This change from baseline reflects the Week 6 FPG minus the baseline FPG. Means are treatment-adjusted for baseline HbA1c, baseline FPG and prior use of insulin, week repeated within patient and week by treatment interaction.
FPG Change From Baseline to Week 12
This change from baseline reflects the Week 12 FPG minus the baseline FPG. Means are treatment-adjusted for baseline HbA1c, baseline FPG and prior use of insulin, week repeated within patient and week by treatment interaction.
FPG Change From Baseline to Week 18
This change from baseline reflects the Week 18 FPG minus the baseline FPG. Means are treatment-adjusted for baseline HbA1c, baseline FPG and prior use of insulin, week repeated within patient and week by treatment interaction.
Percentage of Patients With HbA1c <7.0% at Week 24
The percentage of patients with an HbA1c value below 7% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 7%. Only patients with baseline HbA1c >= 7%
Percentage of Patients With HbA1c <7.0% at Week 24
The percentage of patients with an HbA1c value below 7% at week 24 were calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 7%.
Percentage of Patients Who Have a HbA1c Lowering by at Least 0.5% at Week 24
The percentage of patients with an HbA1c reduction of ≥0.5% at week 24 from baseline was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c reduction less than 0.5%
Number of Patients With Rescue Therapy
The use of rescue therapy was planned for patients failing to achieve preset criteria based on glucose levels during the randomised treatment period of the trial
Full Information
NCT ID
NCT01084005
First Posted
March 9, 2010
Last Updated
December 11, 2013
Sponsor
Boehringer Ingelheim
Collaborators
Eli Lilly and Company
1. Study Identification
Unique Protocol Identification Number
NCT01084005
Brief Title
Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes
Official Title
A Phase III Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of Linagliptin (5 mg) Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients (Age >= 70 Years) With Insufficient Glycaemic Control( HbA1c >= 7.0) Despite Metformin and/or Sulphonylurea and/or Insulin Therapy
Study Type
Interventional
2. Study Status
Record Verification Date
December 2013
Overall Recruitment Status
Completed
Study Start Date
March 2010 (undefined)
Primary Completion Date
June 2011 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
Collaborators
Eli Lilly and Company
4. Oversight
5. Study Description
Brief Summary
The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to placebo given for 24 weeks as add-on therapy to stable treatment in elderly patients with T2DM with insufficient glycaemic control
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
241 (Actual)
8. Arms, Groups, and Interventions
Arm Title
linagliptin
Arm Type
Experimental
Arm Description
patients receive linagliptin 5 mg tablets once daily
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
patients receive placebo tablets matching linagliptin 5 mg once daily
Intervention Type
Drug
Intervention Name(s)
linagliptin
Intervention Description
patients receive linagliptin 5 mg tablets once daily
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
patients receive placebo matching linagliptin 5 mg once daily
Primary Outcome Measure Information:
Title
HbA1c Change From Baseline to Week 24
Description
HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and prior use of insulin.
Time Frame
Baseline and week 24
Secondary Outcome Measure Information:
Title
HbA1c Change From Baseline to Week 6
Description
HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 6 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and prior use of insulin.
Time Frame
Baseline and week 6
Title
HbA1c Change From Baseline to Week 12
Description
HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and prior use of insulin.
Time Frame
Baseline and week 12
Title
HbA1c Change From Baseline to Week 18
Description
HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and prior use of insulin.
Time Frame
Baseline and week 18
Title
FPG Change From Baseline to Week 24
Description
This change from baseline reflects the Week 24 FPG minus the baseline FPG. Means are treatment-adjusted for baseline HbA1c, baseline FPG and prior use of insulin.
Time Frame
Baseline and week 24
Title
FPG Change From Baseline to Week 6
Description
This change from baseline reflects the Week 6 FPG minus the baseline FPG. Means are treatment-adjusted for baseline HbA1c, baseline FPG and prior use of insulin, week repeated within patient and week by treatment interaction.
Time Frame
Baseline and week 6
Title
FPG Change From Baseline to Week 12
Description
This change from baseline reflects the Week 12 FPG minus the baseline FPG. Means are treatment-adjusted for baseline HbA1c, baseline FPG and prior use of insulin, week repeated within patient and week by treatment interaction.
Time Frame
Baseline and week 12
Title
FPG Change From Baseline to Week 18
Description
This change from baseline reflects the Week 18 FPG minus the baseline FPG. Means are treatment-adjusted for baseline HbA1c, baseline FPG and prior use of insulin, week repeated within patient and week by treatment interaction.
Time Frame
Baseline and week 18
Title
Percentage of Patients With HbA1c <7.0% at Week 24
Description
The percentage of patients with an HbA1c value below 7% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 7%. Only patients with baseline HbA1c >= 7%
Time Frame
Baseline and week 24
Title
Percentage of Patients With HbA1c <7.0% at Week 24
Description
The percentage of patients with an HbA1c value below 7% at week 24 were calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 7%.
Time Frame
Baseline and week 24
Title
Percentage of Patients Who Have a HbA1c Lowering by at Least 0.5% at Week 24
Description
The percentage of patients with an HbA1c reduction of ≥0.5% at week 24 from baseline was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c reduction less than 0.5%
Time Frame
Baseline and week 24
Title
Number of Patients With Rescue Therapy
Description
The use of rescue therapy was planned for patients failing to achieve preset criteria based on glucose levels during the randomised treatment period of the trial
Time Frame
week 24
10. Eligibility
Sex
All
Minimum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
Type 2 diabetes mellitus
HbA1c >= 7.0%
Age >= 70 years
Signed and dated written informed consent
Exclusion criteria:
Myocardial infarction, stroke or TIA within 3 months prior to informed consent
Impaired hepatic function
Treatment with glitazones, GLP-1 analogues, DPP-4 inhibitors or rapid acting or pre-mixed insulins
Treatment with anti-obesity drugs
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1218.63.61005 Boehringer Ingelheim Investigational Site
City
Gosford
State/Province
New South Wales
Country
Australia
Facility Name
1218.63.61006 Boehringer Ingelheim Investigational Site
City
Herston
State/Province
Queensland
Country
Australia
Facility Name
1218.63.61003 Boehringer Ingelheim Investigational Site
City
Adelaide
State/Province
South Australia
Country
Australia
Facility Name
1218.63.61002 Boehringer Ingelheim Investigational Site
City
Daw Park
State/Province
South Australia
Country
Australia
Facility Name
1218.63.61007 Boehringer Ingelheim Investigational Site
City
East Ringwood
State/Province
Victoria
Country
Australia
Facility Name
1218.63.61001 Boehringer Ingelheim Investigational Site
City
Parkville
State/Province
Victoria
Country
Australia
Facility Name
1218.63.61004 Boehringer Ingelheim Investigational Site
City
Reservoir
State/Province
Victoria
Country
Australia
Facility Name
1218.63.10008 Boehringer Ingelheim Investigational Site
City
Vancouver
State/Province
British Columbia
Country
Canada
Facility Name
1218.63.10003 Boehringer Ingelheim Investigational Site
City
Hamilton
State/Province
Ontario
Country
Canada
Facility Name
1218.63.10005 Boehringer Ingelheim Investigational Site
City
Hawkesbury
State/Province
Ontario
Country
Canada
Facility Name
1218.63.10007 Boehringer Ingelheim Investigational Site
City
Newmarket
State/Province
Ontario
Country
Canada
Facility Name
1218.63.10006 Boehringer Ingelheim Investigational Site
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
1218.63.10001 Boehringer Ingelheim Investigational Site
City
Montreal
State/Province
Quebec
Country
Canada
Facility Name
1218.63.10002 Boehringer Ingelheim Investigational Site
City
St-Romuald
State/Province
Quebec
Country
Canada
Facility Name
1218.63.10004 Boehringer Ingelheim Investigational Site
City
Saskatoon
State/Province
Saskatchewan
Country
Canada
Facility Name
1218.63.45007 Boehringer Ingelheim Investigational Site
City
Aalborg
Country
Denmark
Facility Name
1218.63.45002 Boehringer Ingelheim Investigational Site
City
Aarhus C
Country
Denmark
Facility Name
1218.63.45003 Boehringer Ingelheim Investigational Site
City
Aarhus C
Country
Denmark
Facility Name
1218.63.45001 Boehringer Ingelheim Investigational Site
City
Birkerød
Country
Denmark
Facility Name
1218.63.45008 Boehringer Ingelheim Investigational Site
City
Hellerup
Country
Denmark
Facility Name
1218.63.45006 Boehringer Ingelheim Investigational Site
City
Hillerød
Country
Denmark
Facility Name
1218.63.45004 Boehringer Ingelheim Investigational Site
City
Hvidovre
Country
Denmark
Facility Name
1218.63.45005 Bispebjerg Hospital
City
København NV
Country
Denmark
Facility Name
1218.63.31008 Boehringer Ingelheim Investigational Site
City
Beek en Donk
Country
Netherlands
Facility Name
1218.63.31007 Boehringer Ingelheim Investigational Site
City
Beerzerveld
Country
Netherlands
Facility Name
1218.63.31012 Boehringer Ingelheim Investigational Site
City
Doetinchem
Country
Netherlands
Facility Name
1218.63.31014 Boehringer Ingelheim Investigational Site
City
Etten-Leur
Country
Netherlands
Facility Name
1218.63.31009 Boehringer Ingelheim Investigational Site
City
Oude Pekela
Country
Netherlands
Facility Name
1218.63.31001 Boehringer Ingelheim Investigational Site
City
Tubbergen
Country
Netherlands
Facility Name
1218.63.46004 Boehringer Ingelheim Investigational Site
City
Göteborg
Country
Sweden
Facility Name
1218.63.46003 Boehringer Ingelheim Investigational Site
City
Järfälla
Country
Sweden
Facility Name
1218.63.46001 Boehringer Ingelheim Investigational Site
City
Malmö
Country
Sweden
Facility Name
1218.63.46002 Boehringer Ingelheim Investigational Site
City
Sundsvall
Country
Sweden
Facility Name
1218.63.46005 Boehringer Ingelheim Investigational Site
City
Uppsala
Country
Sweden
12. IPD Sharing Statement
Citations:
PubMed Identifier
25236917
Citation
Lajara R, Aguilar R, Hehnke U, Woerle HJ, von Eynatten M. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials. Clin Ther. 2014 Nov 1;36(11):1595-605. doi: 10.1016/j.clinthera.2014.07.020. Epub 2014 Sep 16.
Results Reference
derived
PubMed Identifier
24169807
Citation
McGill JB, Barnett AH, Lewin AJ, Patel S, Neubacher D, von Eynatten M, Woerle HJ. Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment. Diab Vasc Dis Res. 2014 Jan;11(1):34-40. doi: 10.1177/1479164113507068. Epub 2013 Oct 29.
Results Reference
derived
PubMed Identifier
23948125
Citation
Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle HJ. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet. 2013 Oct 26;382(9902):1413-23. doi: 10.1016/S0140-6736(13)61500-7. Epub 2013 Aug 13.
Results Reference
derived
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1218/1218.63_U11-1781-02.pdf
Description
Related Info
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1218/1218.63_Literature.pdf
Description
Related Info
Learn more about this trial
Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes
We'll reach out to this number within 24 hrs